It is important, therefore, to develop a more complete understanding of these processes to allow effective targeting of IFN-responsive pathways and to facilitate the development of an immunotherapeutic armoury designed to attenuate β-cell loss in type 1 diabetes. The gene discussed is IFNA1; the disease is type 1 diabetes mellitus.